What removing the DNA synthesis bottleneck means for the future of drug discovery and development

Elizabeth Wood, CEO of Jura Bio, tells David McCall, Senior Editor, BioInsights, about the sheer scale of the opportunity for biopharma presented by combined innovations in DNA synthesis and machine learning.

Please enter your email to access content Read now